U.S. Over the Counter Drugs Market Size, Growth Trends 2034

U.S. Over the Counter (OTC) Drugs Market Size - By Drug Category, By Formulation Type, By Distribution Channel, Growth Forecast, 2025 - 2034

Report Content

Chapter 1&nbsp;&nbsp;&nbsp;Methodology and Scope

1.1&nbsp;&nbsp;&nbsp; Market scope and definition

1.2&nbsp;&nbsp;&nbsp; Research design

1.2.1&nbsp;&nbsp;&nbsp; Research approach

1.2.2&nbsp;&nbsp;&nbsp; Data collection methods

1.3&nbsp;&nbsp;&nbsp; Data mining sources

1.4&nbsp;&nbsp;&nbsp; Base estimates and calculations

1.4.1&nbsp;&nbsp;&nbsp; Base year calculation

1.4.2&nbsp;&nbsp;&nbsp; Key trends for market estimation

1.5&nbsp;&nbsp;&nbsp; Primary research and validation

1.5.1&nbsp;&nbsp;&nbsp; Primary sources

1.6&nbsp;&nbsp;&nbsp; Forecast model

1.7&nbsp;&nbsp;&nbsp; Research assumptions and limitations

Chapter 2&nbsp;&nbsp;&nbsp;Executive Summary

2.1&nbsp;&nbsp;&nbsp; Industry 3600 synopsis

2.2&nbsp;&nbsp;&nbsp; Key market trends

2.2.1&nbsp;&nbsp;&nbsp; Business trends

2.2.2&nbsp;&nbsp;&nbsp; Zone trends

2.2.3&nbsp;&nbsp;&nbsp; Drug category trends

2.2.4&nbsp;&nbsp;&nbsp; Formulation type trends

2.2.5&nbsp;&nbsp;&nbsp; Distribution channel trends

2.3&nbsp;&nbsp;&nbsp; CXO perspectives: Strategic imperatives

2.3.1&nbsp;&nbsp;&nbsp; Key decision points for industry executives

2.3.2&nbsp;&nbsp;&nbsp; Critical success factors for market players

2.4&nbsp;&nbsp;&nbsp; Future outlook and strategic recommendations

Chapter 3&nbsp;&nbsp;&nbsp;Industry Insights

3.1&nbsp;&nbsp;&nbsp; Industry ecosystem analysis

3.1.1&nbsp;&nbsp;&nbsp; Supplier landscape

3.1.2&nbsp;&nbsp;&nbsp; Value addition at each stage

3.1.3&nbsp;&nbsp;&nbsp; Factors affecting the value chain

3.2&nbsp;&nbsp;&nbsp; Industry impact forces

3.2.1&nbsp;&nbsp;&nbsp; Growth drivers

3.2.1.1&nbsp;&nbsp;&nbsp; Growing consumer awareness of self-medication and disease management

3.2.1.2&nbsp;&nbsp;&nbsp; High cost of prescription drugs leading to a shift towards OTC drugs

3.2.1.3&nbsp;&nbsp;&nbsp; Favorable regulatory support for OTC drug approvals

3.2.1.4&nbsp;&nbsp;&nbsp; Expansion of digital commerce and e-pharmacy platforms

3.2.1.5&nbsp;&nbsp;&nbsp; Rising prevalence of chronic diseases

3.2.2&nbsp;&nbsp;&nbsp; Industry pitfalls and challenges

3.2.2.1&nbsp;&nbsp;&nbsp; Concern towards misuse or risk of self-diagnosis

3.2.2.2&nbsp;&nbsp;&nbsp; Potential side effects and interactions due to medication

3.2.3&nbsp;&nbsp;&nbsp; Market opportunities

3.2.3.1&nbsp;&nbsp;&nbsp; Increasing shift towards natural and herbal OTC products

3.2.3.2&nbsp;&nbsp;&nbsp; Expanding women&#39;s health and specialty segments

3.3&nbsp;&nbsp;&nbsp; Growth potential analysis

3.4&nbsp;&nbsp;&nbsp; Regulatory landscape

3.5&nbsp;&nbsp;&nbsp; Future market trends

3.6&nbsp;&nbsp;&nbsp; Prescription to nonprescription switch list

3.7&nbsp;&nbsp;&nbsp; Pipeline analysis

3.8&nbsp;&nbsp;&nbsp; Porter&#39;s analysis

3.9&nbsp;&nbsp;&nbsp; PESTEL analysis

Chapter 4&nbsp;&nbsp;&nbsp;Competitive Landscape, 2024

4.1&nbsp;&nbsp;&nbsp; Introduction

4.2&nbsp;&nbsp;&nbsp; Company matrix analysis

4.3&nbsp;&nbsp;&nbsp; Company market share analysis

4.4&nbsp;&nbsp;&nbsp; Competitive analysis of major market players

4.5&nbsp;&nbsp;&nbsp; Competitive positioning matrix

4.6&nbsp;&nbsp;&nbsp; Strategy dashboard

4.6.1&nbsp;&nbsp;&nbsp; Merger and acquisition

4.6.2&nbsp;&nbsp;&nbsp; Partnership and collaboration

4.6.3&nbsp;&nbsp;&nbsp; New product launches

4.6.4&nbsp;&nbsp;&nbsp; Expansion plans

Chapter 5&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Drug Category, 2021 - 2034 ($ Mn)

5.1&nbsp;&nbsp;&nbsp; Key trends

5.2&nbsp;&nbsp;&nbsp; Cold and cough remedies

5.3&nbsp;&nbsp;&nbsp; Vitamins and supplements

5.4&nbsp;&nbsp;&nbsp; Digestive and intestinal remedies

5.5&nbsp;&nbsp;&nbsp; Skin treatment

5.6&nbsp;&nbsp;&nbsp; Analgesics

5.7&nbsp;&nbsp;&nbsp; Sleeping aids

5.8&nbsp;&nbsp;&nbsp; Other drug categories

Chapter 6&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Formulation Type, 2021 - 2034 ($ Mn)

6.1&nbsp;&nbsp;&nbsp; Key trends

6.2&nbsp;&nbsp;&nbsp; Tablets

6.3&nbsp;&nbsp;&nbsp; Liquids

6.4&nbsp;&nbsp;&nbsp; Ointments

6.5&nbsp;&nbsp;&nbsp; Sprays

Chapter 7&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Distribution Channel, 2021 - 2034 ($ Mn)

7.1&nbsp;&nbsp;&nbsp; Key trends

7.2&nbsp;&nbsp;&nbsp; Online channels

7.3&nbsp;&nbsp;&nbsp; Offline channels

7.3.1&nbsp;&nbsp;&nbsp; Hospital pharmacies

7.3.2&nbsp;&nbsp;&nbsp; Retail pharmacies

7.3.3&nbsp;&nbsp;&nbsp; Other offline channels

Chapter 8&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Country, 2021 - 2034 ($ Mn)

8.1&nbsp;&nbsp;&nbsp; Key trends

8.2&nbsp;&nbsp;&nbsp; North East

8.2.1&nbsp;&nbsp;&nbsp; Connecticut

8.2.2&nbsp;&nbsp;&nbsp; Maine

8.2.3&nbsp;&nbsp;&nbsp; Massachusetts

8.2.4&nbsp;&nbsp;&nbsp; New Hampshire

8.2.5&nbsp;&nbsp;&nbsp; Rhode Island

8.2.6&nbsp;&nbsp;&nbsp; Vermont

8.2.7&nbsp;&nbsp;&nbsp; New Jersey

8.2.8&nbsp;&nbsp;&nbsp; New York

8.2.9&nbsp;&nbsp;&nbsp; Pennsylvania

8.3&nbsp;&nbsp;&nbsp; East North Central

8.3.1&nbsp;&nbsp;&nbsp; Wisconsin

8.3.2&nbsp;&nbsp;&nbsp; Michigan

8.3.3&nbsp;&nbsp;&nbsp; Illinois

8.3.4&nbsp;&nbsp;&nbsp; Indiana

8.3.5&nbsp;&nbsp;&nbsp; Ohio

8.4&nbsp;&nbsp;&nbsp; West North Central

8.4.1&nbsp;&nbsp;&nbsp; North Dakota

8.4.2&nbsp;&nbsp;&nbsp; South Dakota

8.4.3&nbsp;&nbsp;&nbsp; Nebraska

8.4.4&nbsp;&nbsp;&nbsp; Kansas

8.4.5&nbsp;&nbsp;&nbsp; Minnesota

8.4.6&nbsp;&nbsp;&nbsp; Iowa

8.4.7&nbsp;&nbsp;&nbsp; Missouri

8.5&nbsp;&nbsp;&nbsp; South Atlantic

8.5.1&nbsp;&nbsp;&nbsp; Delaware

8.5.2&nbsp;&nbsp;&nbsp; Maryland

8.5.3&nbsp;&nbsp;&nbsp; District of Columbia

8.5.4&nbsp;&nbsp;&nbsp; Virginia

8.5.5&nbsp;&nbsp;&nbsp; West Virginia

8.5.6&nbsp;&nbsp;&nbsp; North Carolina

8.5.7&nbsp;&nbsp;&nbsp; South Carolina

8.5.8&nbsp;&nbsp;&nbsp; Georgia

8.5.9&nbsp;&nbsp;&nbsp; Florida

8.6&nbsp;&nbsp;&nbsp; East South Central

8.6.1&nbsp;&nbsp;&nbsp; Kentucky

8.6.2&nbsp;&nbsp;&nbsp; Tennessee

8.6.3&nbsp;&nbsp;&nbsp; Mississippi

8.6.4&nbsp;&nbsp;&nbsp; Alabama

8.7&nbsp;&nbsp;&nbsp; West South Central

8.7.1&nbsp;&nbsp;&nbsp; Oklahoma

8.7.2&nbsp;&nbsp;&nbsp; Texas

8.7.3&nbsp;&nbsp;&nbsp; Arkansas

8.7.4&nbsp;&nbsp;&nbsp; Louisiana

8.8&nbsp;&nbsp;&nbsp; Mountain States

8.8.1&nbsp;&nbsp;&nbsp; Idaho

8.8.2&nbsp;&nbsp;&nbsp; Montana

8.8.3&nbsp;&nbsp;&nbsp; Wyoming

8.8.4&nbsp;&nbsp;&nbsp; Nevada

8.8.5&nbsp;&nbsp;&nbsp; Utah

8.8.6&nbsp;&nbsp;&nbsp; Colorado

8.8.7&nbsp;&nbsp;&nbsp; Arizona

8.8.8&nbsp;&nbsp;&nbsp; New Mexico

8.9&nbsp;&nbsp;&nbsp; Pacific Central

8.9.1&nbsp;&nbsp;&nbsp; California

8.9.2&nbsp;&nbsp;&nbsp; Alaska

8.9.3&nbsp;&nbsp;&nbsp; Hawaii

8.9.4&nbsp;&nbsp;&nbsp; Oregon

8.9.5&nbsp;&nbsp;&nbsp; Washington

Chapter 9&nbsp;&nbsp;&nbsp;Company Profiles

9.1&nbsp;&nbsp;&nbsp; Abbott Laboratories

9.2&nbsp;&nbsp;&nbsp; Alkem Laboratories

9.3&nbsp;&nbsp;&nbsp; Bayer

9.4&nbsp;&nbsp;&nbsp; Cipla

9.5&nbsp;&nbsp;&nbsp; Dr. Reddy&rsquo;s Laboratories

9.6&nbsp;&nbsp;&nbsp; Glenmark Pharmaceuticals

9.7&nbsp;&nbsp;&nbsp; Haleon

9.8&nbsp;&nbsp;&nbsp; Himalaya Wellness Company

9.9&nbsp;&nbsp;&nbsp; Kenvue

9.10&nbsp;&nbsp;&nbsp; Perrigo Company

9.11&nbsp;&nbsp;&nbsp; Piramal Pharma

9.12&nbsp;&nbsp;&nbsp; Procter &amp; Gamble Company

9.13&nbsp;&nbsp;&nbsp; Reckitt

9.14&nbsp;&nbsp;&nbsp; Sanofi

9.15&nbsp;&nbsp;&nbsp; Stada Arzneimittel

9.16&nbsp;&nbsp;&nbsp; Sun Pharma

9.17&nbsp;&nbsp;&nbsp; Taisho Pharmaceutical

9.18&nbsp;&nbsp;&nbsp; Teva Pharmaceutical 
&nbsp;

U.S. Over the Counter (OTC) Drugs Market

Inquiry Before Buying